semaglutide and non alcoholic fatty liver disease Why are GLP-1 agonists being used to treat patients with nonalcoholic disease? Role of semaglutide in the

A type 2 diabetes patient might take anywhere from 10 to 80+ units daily, adjusted based on fasting glucose readings

Clinical trials show a dramatic difference: Zepbound (SURMOUNT Trials) Source: SURMOUNT clinical trial program [1] Saxenda (SCALE Trials) Source: SCALE clinical trial program [2] What This Means At higher doses, Zepbound produces roughly 2-3 times more weight loss than Saxenda (results vary by dose, diabetes status, and individual response)

S.AhnJ.HanI.ParkH.et al (2016)

Do GLP-1 receptor agonists increase the risk of breast cancer

Fifth Meeting of the International Society of Haematology IV:37, 1979